Antibody–drug conjugates (ADCs) are often referred to as “biological missiles”. They use a linker to conjugate highly potent small‑molecule toxins (such as MMAE, DM1, SN‑38) to a targeting antibody, enabling precise killing of tumour cells. However, the preparation of ADCs places extreme demands on the reaction environment. On one hand, toxin molecules and linker intermediates are highly sensitive to oxygen and moisture; oxidation or hydrolysis can directly cause conjugation failure or increase product heterogeneity. On the other hand, clinical‑grade ADCs must be prepared under sterile conditions to avoid microbial contamination. Conventional biosafety cabinets cannot provide an anaerobic environment, while ordinary gloveboxes lack sterility assurance. High‑performance gloveboxes that combine sterile interfaces with an inert atmosphere sit exactly at the intersection of “bio‑inertness” and “sterility”, offering an ideal solution for ADC research, development and pilot production.
1. Environmental Sensitivity and Core Challenges in ADC Synthesis
ADC synthesis generally consists of three key steps: antibody activation/modification, synthesis or activation of the linker‑toxin, and the conjugation reaction itself. Many chemically sensitive substances are involved:
- Payload (toxin): Taking MMAE (monomethyl auristatin E) as an example, the hydroxyl and amino groups in its structure are easily oxidised in air, leading to loss of toxin activity. Some toxins (such as the maytansinoid DM1) undergo ring‑opening degradation in the presence of moisture.
- Linker: Cleavable linkers often contain disulfide bonds, hydrazone bonds or peptide bonds, which can be hydrolysed by trace acids or water. Non‑cleavable linkers containing maleimide groups are also highly moisture‑sensitive; after hydrolysis they can no longer react with thiol groups on the antibody.
- Antibody: Although antibodies themselves are relatively stable, they may aggregate or denature during repeated freeze‑thaw cycles or when exposed to non‑physiological pH. More critically, the thiol groups on the antibody (generated by partial reduction of inter‑chain disulfide bonds) are extremely susceptible to oxidation by air, forming disulfide crosslinks and reducing conjugation efficiency.
Problems with conventional operation: On a standard lab bench or in a biosafety cabinet, the oxygen concentration is about 21% and relative humidity is typically 30‑60%. Performing ADC conjugation in such an environment inevitably leads to 5‑15% oxidative by‑products, even when time is carefully controlled, resulting in broad drug‑to‑antibody ratio (DAR) distribution, high residual free toxin, and poor batch‑to‑batch consistency. Moreover, aseptic operation requires additional laminar flow hoods or isolators, which cannot be combined easily with inert gas protection.
2. Dual Capabilities of a High‑Performance Glovebox: Inert + Sterile
A high‑performance glovebox achieves the integration of a bio‑inert atmosphere and a sterile environment through the following technologies:
2.1 Anhydrous, oxygen‑free inert atmosphere
- Dual‑purifier recirculation system: continuously removes water and oxygen from the glovebox atmosphere; typical specifications: H₂O <0.1 ppm, O₂ <0.1 ppm.
- Choice of high‑purity argon or nitrogen – for systems that react with nitrogen (e.g. certain metal catalysts), argon is used.
- Positive pressure maintained (typically 5‑15 mbar above ambient): prevents ingress of external air.
2.2 Sterility integration
- Chamber material: 316L stainless steel, internally electropolished (Ra <0.4 μm), with no dead corners.
- Sterilisation function: integrated VHP (vaporised hydrogen peroxide) generator that circulates and sterilises all internal surfaces and built‑in equipment, achieving 6‑log spore inactivation.
- Sterile transfer: equipped with a dual‑door rapid transfer port (RTP) or a vacuum antechamber with sterilisation capability, allowing aseptic transfer of materials.
- Online monitoring: built‑in ports for settle plates, airborne particle counters and optional viable air samplers.
Such a configuration meets both ISO Class 5 (Class 100) cleanliness and anaerobic/low‑oxygen requirements, making it an ideal platform for ADC conjugation, radiopharmaceutical labelling, aseptic filling and other demanding operations.
3. Full‑Process ADC Synthesis Inside a Glovebox
Taking a typical cysteine‑based ADC (e.g. using the traditional maleimide linker or ThioBridge™ technology), the standard operating procedure inside a glovebox is as follows:
| Step | Operation | Key points performed inside the glovebox |
|---|---|---|
| 1. Partial antibody reduction | Antibody (e.g. trastuzumab) dissolved in buffer; add TCEP or DTT to partially reduce inter‑chain disulfide bonds, generating free thiols. | Buffer must be pre‑degassed (e.g. sparged with argon for 30 min). The entire reduction is performed under inert atmosphere to prevent thiol oxidation. |
| 2. Linker‑toxin activation | Weigh out linker‑toxin (e.g. MC‑VC‑PAB‑MMAE) and dissolve in DMSO or DMA. | Reagent opening and weighing are done inside the glovebox; solvents are dried over molecular sieves (water <0.01%) before use. |
| 3. Conjugation reaction | Add activated linker‑toxin to the antibody solution at a defined molar ratio (typically 5‑10× excess). Control pH (6.5‑7.5), temperature (25‑30 °C) and time (1‑4 h). | Temperature is precisely controlled via a built‑in magnetic stirrer with hotplate, or a constant‑temperature water bath. Sampling is performed online to monitor conjugation progress. |
| 4. Quenching and purification | Add excess cysteine or N‑acetylcysteine to quench unreacted linker‑toxin. | After quenching, the sample is transferred to a purification system coupled to the glovebox (e.g. an AKTA chromatography system) for desalting or hydrophobic interaction chromatography (HIC) to remove free toxin and organic solvent. |
| 5. Formulation and filling | Exchange the purified ADC into formulation buffer (e.g. histidine‑sucrose), adjust concentration, and sterilise by 0.22 µm membrane filtration. | The filtered sample can be dispensed directly into sterile cryovials or vials, partially stoppered, and transferred to a freeze‑dryer or cold storage. |
| 6. In‑process quality control | Take samples for DAR measurement (by HIC or LC‑MS), residual free toxin, and aggregate content (SEC‑HPLC). | A small HPLC injector can be installed inside the glovebox, or samples are transferred via a sealed pass‑through for analysis outside. |
Key data: One ADC R&D team compared the same conjugation process performed in a conventional fume hood (ambient air) versus a high‑performance glovebox (H₂O/O₂ <0.1 ppm, pre‑sterilised by VHP). For the glovebox group, the average DAR was 4.0±0.1, free toxin <0.5%, and oxidative impurities (e.g. hydrolysed maleimide) <0.2%. In the air group, the average DAR was 3.5±0.6, free toxin as high as 2.5%, and oxidative impurities up to 3.8%. More importantly, the three‑batch deviation in the glovebox group was only 0.05, satisfying the batch‑to‑batch consistency requirements for an IND filing.
4. Beyond Conjugation: Extended ADC‑Related Applications of a Glovebox
Beyond the core conjugation step, a high‑performance glovebox can also empower the following ADC R&D activities:
4.1 Early‑stage synthesis of linker‑toxins
Many ADCs use novel toxins (e.g. PBD dimers, camptothecin derivatives) whose intermediate synthesis involves air‑sensitive catalysts (such as Pd/C, hydrogenation reactions) or moisture‑sensitive reagents (e.g. EDC, HATU). Placing the entire synthesis setup (round‑bottom flasks, addition funnels, rotary evaporator interfaces) inside a glovebox enables multi‑step synthesis under strictly anhydrous, oxygen‑free conditions.
4.2 Radiolabelled ADCs
Radiolabelled ADCs (e.g. ¹⁷⁷Lu‑ADC, ⁸⁹Zr‑ADC) for diagnostic or therapeutic applications must be prepared in a tightly controlled environment to prevent radionuclide leakage and oxidation. A glovebox can be equipped with lead shielding and radiation monitoring probes, protecting operators while maintaining an inert atmosphere.
4.3 Sample preparation for cytotoxicity assays
In‑vitro cytotoxicity testing of ADCs requires a series of sample dilutions. Preparing these dilutions and aliquots in an inert environment avoids underestimation of activity due to oxidation, ensuring accurate IC₅₀ data.
4.4 Forced degradation studies in stability research
Inside a glovebox, microenvironments with different humidity and oxygen levels can be created to study ADC degradation pathways under specific conditions – for example, placing saturated salt solutions to achieve precise relative humidity, or introducing low‑concentration oxygen/nitrogen mixtures to simulate transport conditions.
5. Selection Guide: Core Configuration of a High‑Performance Glovebox for ADCs
To meet the specific needs of ADC synthesis and pilot production, the following aspects should be considered when selecting a glovebox:
| Requirement | Recommended configuration | Detailed explanation |
|---|---|---|
| Inertness level | H₂O <0.1 ppm, O₂ <0.1 ppm | Dual purifier columns, auto‑regeneration, redundant H₂O/O₂ sensors |
| Sterility assurance | VHP sterilisation system + HEPA/ULPA filtration | Programmable sterilisation cycles, with circulation and H₂O₂ decomposition module |
| Material compatibility | Electropolished 316L interior, chemical‑resistant seals | Resists DMSO, DMA, acetonitrile and other organic solvents; prevents swelling of gaskets |
| Material transfer | RTP port (270 mm diameter) or double‑door sterilisation chamber | Enables seamless sterile connection to external isolators or RABS |
| Built‑in equipment | Precision balance (0.01‑100 g), magnetic stirrers, syringe pumps, low‑temperature circulating bath | Must be spark‑free, easy to clean, and compatible with VHP sterilisation |
| Cleaning and drainage | Tiltable bottom plate, integrated drain valve | Facilitates collection and cleaning of spilled liquids |
| Data recording | SCADA system with electronic signature (21 CFR Part 11 compliant) | Supports audit trails in a GMP environment |
Special advice: If different ADCs (with different linker‑toxins) are being developed simultaneously, choose a dual‑station glovebox with removable interior dividers to prevent cross‑contamination. For users planning pilot‑scale production (batch size ≥10 g of antibody), a custom extended glovebox (≥3 m) that can house a medium‑pressure chromatography system and a hollow‑fibre tangential flow filtration module should be considered.
6. Regulatory Compliance: Bridging from R&D to the Clinic
ADCs intended for human use must be manufactured in compliance with GMP guidelines. As an isolator, a high‑performance glovebox helps users meet regulatory requirements in the following ways:
- Environmental monitoring: Built‑in ports for online particle counting and viable air sampling support verification of Grade A clean zones as required by GMP.
- SOP support: Detailed VHP sterilisation validation reports, leak rate test methods, and internal cleaning procedures are provided.
- Cleanable design: Radiused corners, no exposed threads, quick‑change glove rings – all facilitate regular disinfection and validation.
Many ADC contract development and manufacturing organisations (CDMOs) have already adopted integrated glovebox isolators as the core equipment for their conjugation processes and have successfully passed FDA and EMA site inspections. Such equipment unifies the seemingly contradictory requirements of chemical inertness and biological sterility, paving the way for ADCs to move from the laboratory to commercialisation.
Conclusion: Building a “Zero‑Disturbance” Reaction Space for ADC R&D
The success of antibody–drug conjugates depends on the precise formation of every chemical bond and the complete preservation of every biological activity. Oxygen, moisture and microorganisms in a conventional environment act as invisible “disturbers”, constantly eroding conjugation efficiency and product quality. By enclosing the reaction space in a cross‑boundary environment that is anhydrous, oxygen‑free, and sterile, a high‑performance glovebox allows researchers to focus on the chemistry and biology itself, rather than fighting against environmental fluctuations.
We offer the Bio‑Inert™ series gloveboxes specifically designed for ADC R&D, integrating VHP sterilisation, low‑oxygen control, and modular process interfaces. Whether for milligram‑level screening or gram‑scale pilot runs, we can tailor a solution to your needs.
